Waverly Advisors LLC Trims Stake in Medpace Holdings, Inc. $MEDP

Waverly Advisors LLC lowered its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 54.1% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,803 shares of the company's stock after selling 2,128 shares during the period. Waverly Advisors LLC's holdings in Medpace were worth $955,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of MEDP. Johnson Financial Group Inc. purchased a new position in shares of Medpace during the second quarter worth about $27,000. Elyxium Wealth LLC purchased a new stake in Medpace in the fourth quarter valued at approximately $30,000. Jones Financial Companies Lllp purchased a new stake in Medpace in the second quarter valued at approximately $30,000. Allied Private Wealth LLC bought a new stake in Medpace during the second quarter valued at approximately $31,000. Finally, Kilter Group LLC bought a new stake in Medpace during the second quarter valued at approximately $31,000. Hedge funds and other institutional investors own 77.98% of the company's stock.

Insider Buying and Selling at Medpace

In related news, CFO Kevin M. Brady sold 3,400 shares of the company's stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $625.24, for a total transaction of $2,125,816.00. Following the completion of the sale, the chief financial officer directly owned 12,830 shares in the company, valued at $8,021,829.20. This represents a 20.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO August J. Troendle sold 650 shares of the stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $620.27, for a total transaction of $403,175.50. Following the sale, the chief executive officer directly owned 539,894 shares of the company's stock, valued at $334,880,051.38. The trade was a 0.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 134,471 shares of company stock worth $82,151,311 over the last 90 days. Company insiders own 20.50% of the company's stock.

Medpace Price Performance

NASDAQ:MEDP opened at $595.41 on Tuesday. The business has a 50 day moving average of $579.61 and a 200 day moving average of $506.17. The company has a market capitalization of $16.62 billion, a price-to-earnings ratio of 34.90, a PEG ratio of 2.62 and a beta of 1.15. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace's revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Robert W. Baird boosted their price target on shares of Medpace from $547.00 to $624.00 and gave the stock a "neutral" rating in a research note on Friday, July 24th. Barclays set a $600.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Truist Financial lifted their price objective on shares of Medpace from $462.00 to $609.00 and gave the stock a "hold" rating in a report on Friday, July 24th. Weiss Ratings upgraded shares of Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 12th. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a $535.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $595.20.

Medpace Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.